Table 2.
Univariate and multivariate analyses of CSS in ESCC patients.
| Univariate analysis | P-value | Multivariate analysis | P-value | |
|---|---|---|---|---|
| HR (95% CI) | HR (95% CI) | |||
| Age (years) | 0.584 | |||
| ≤ 60 | 1.000 | |||
| > 60 | 0.930 (0.717-1.206) | |||
| Gender | 0.530 | |||
| Female | 1.000 | |||
| Male | 1.105 (0.809-1.510) | |||
| Tumor length (cm) | 0.001 | |||
| ≤ 3.0 | 1.000 | |||
| > 3.0 | 1.634 (1.208-2.211) | |||
| Tumor location | 0.845 | |||
| Upper | 1.000 | |||
| Middle | 1.160 (0.624-2.156) | 0.638 | ||
| Lower | 1.197 (0.644-2.222) | 0.569 | ||
| Vessel invasion | 0.003 | |||
| Negative | 1.000 | |||
| Positive | 1.636 (1.187-2.255) | |||
| Differentiation | 0.075 | |||
| Well | 1.000 | |||
| Moderate | 1.247 (0.834-1.864) | 0.282 | ||
| Poor | 1.660 (1.045-2.638) | 0.032 | ||
| CRP (mg/L) | <0.001 | |||
| ≤ 10.5 | 1.000 | |||
| > 10.5 | 1.896 (1.450-2.479) | |||
| ALB (g/L) | 0.002 | |||
| ≤ 40.5 | 1.000 | |||
| > 40.5 | 0.669 (0.517-0.867) | |||
| PALB (mg/L) | <0.001 | |||
| ≤ 248 | 1.000 | |||
| > 248 | 0.613 (0.474-0.792) | |||
| CPR | <0.001 | 0.008 | ||
| ≤ 0.03 | 1.000 | 1.000 | ||
| > 0.03 | 2.116 (1.634-2.739) | 1.630 (1.135-2.342) | ||
| CAR | <0.001 | 0.052 | ||
| ≤ 0.3 | 1.000 | |||
| > 0.3 | 1.485 (0.997-2.212) | |||
| Adjuvant therapy | 1.000 | 0.329 | ||
| No | 1.149 (0.870-1.517) | |||
| Yes | ||||
| TNM stage | <0.001 | <0.001 | ||
| I | 1.000 | 1.000 | ||
| II | 1.804 (1.237-2.631) | 0.002 | 1.628 (1.111-2.387) | 0.012 |
| III | 3.067 (2.150-4.373) | <0.001 | 2.559 (1.786-3.667) | <0.001 |
| BMI (kg/m2) | ||||
| ≥ 20 | 1.000 | <0.001 | 1.000 | <0.001 |
| < 20 | 2.006 (1.551-2.595) | 1.877 (1.444-2.440) |
ESCC: esophageal squamous cell carcinoma; CRP: C-reactive protein; PALB: prealbumin; ALB: albumin; CPR: C-reactive protein to prealbumin ratio; CAR: C-reactive protein to albumin ratio; TNM: tumor, node, metastasis; BMI: body mass index; CI: confidence interval; HR: hazard ratio.